Patent intelligence · US
US 12384744
Enzyme-cleavable methadone prodrugs and methods of use thereof
Enzyme-cleavable methadone prodrugs and methods of use thereof
Patent details — US 12384744
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 12, 2025
- Expiration
- Aug 7, 2045
- Applicant
- Ensysce Biosciences Inc.
- Claims
- 3
- CPC classes
- A61K, A61K31/245, A61K31/27, A61K45/06
Quick answer
US 12384744 (Enzyme-cleavable methadone prodrugs and methods of use thereof) is held by Ensysce Biosciences Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ensysce Biosciences Inc.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K31/245, A61K31/27, A61K45/06
More from Ensysce Biosciences Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12384744?
US 12384744 (Enzyme-cleavable methadone prodrugs and methods of use thereof) is held by Ensysce Biosciences Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12384744?
Ensysce Biosciences Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12384744 expire?
Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.